This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 9.43% and 9.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Growth Investors Will Love Qiagen (QGEN)
by Zacks Equity Research
Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.
QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.
PerkinElmer's (PKI) Arm Gets FDA EUA Nod for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.
Thermo Fisher (TMO) Boosts COVID Testing With Wastewater Kit
by Zacks Equity Research
Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.
QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.
QGEN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. ILMN: Which Stock Is the Better Value Option?
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
by Trina Mukherjee
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat
by Zacks Equity Research
QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.
QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation
by Zacks Equity Research
QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.
QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 1.52% and 0.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance
by Zacks Equity Research
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.